Breaking Boundaries with Light and Shadow, Sailing Forward from Zhejiang: The Splendid Opening of the 2025 Zhejiang Service Trade (Singapore) Film & Television Exhibition
HANGZHOU, China, Dec. 3, 2025 /PRNewswire/ -- A news report from Department of Commerce of Zhejiang Province: On December 3rd, the 2025 Zhejiang Service Trade (Singapore) Film & Television Exhibition, themed "Service of Zhejiang, Serve the...
TCab Tech E20 eVTOL Successfully Completes Transition Flight Tests
SHANGHAI, Dec. 3, 2025 /PRNewswire/ -- TCab Tech announced today that its full-scale E20 eVTOL demonstrator has successfully completed transition flight tests, marking a critical milestone in the program's development. During the flight campaign,...
The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
CHENGDU, China, Nov. 28, 2025 /PRNewswire/ -- Recently, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic...
Renalys Pharma Announces Positive Topline Results from Phase III Study of Sparsentan in Japanese Patients with IgA Nephropathy
– In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy (N=35), the percent change from baseline in the 24-hour urine protein-to-creatinine ratio at Week 36, which was the study's...
Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population
SAN FRANCISCO and SUZHOU, China, Nov. 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...
Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN) BPDCN is a highly aggressive, orphan hematologic malignancy that primarily affects skin,...
Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
CHENGDU, China, Nov. 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study...
Beyfortus® (nirsevimab) now available in Malaysia to protect all infants against RSV disease
Beyfortus® (nirsevimab) is an available option designed to protect all infants – whether born full-term or pre-term, healthy or with underlying conditions – against respiratory syncytial virus (RSV), with proven high and sustained efficacy, a...
AI-Powered Subscription Solutions by Subotiz Featured at Singapore FinTech Festival 2025
SINGAPORE, Nov. 21, 2025 /PRNewswire/ -- Subotiz, an emerging fintech platform powering AI-driven subscription and payment solutions, was recently featured at the Singapore FinTech Festival (SFF 2025), a global stage for innovation in finance and...
SUS ENVIRONMENT at COP30: Co-building a Brighter Tomorrow with Waste-to-Energy
SHANGHAI, Nov. 20, 2025 /PRNewswire/ -- From November 10 to 21, 2025, the 30th United Nations Climate Change Conference (COP 30) was held in Belem, Brazil. Over 50,000 delegates from more than 190 countries and regions attended, jointly advancing...